

Claims

1. A p53 binding region of a CD95 receptor DNA.
2. The p53 binding region according to claim 1, which comprises the sequence of fig. 4 and/or fig. 5 or a sequence differing therefrom by one or several base pairs.
3. The p53 binding region according to claim 2, which comprises the sequence of figures 7, 8, 9, 10, 11, 12 or 13.
4. A vector comprising the p53 binding region according to any of claims 1 to 3.
5. The vector according to claim 4, wherein the vector is selected from the group consisting of CD95(Ps)-LUC, CD95(P)-LUC, CD95(I+SV)-LUC, CD95(Ps+I)-LUC, p1139, p1140, p1141, p1142, p1140 IMI, p1140 IMII, p1140 IMIII, p1140 IMIV, p1141 IMIII, p1141 1p53, p1141 2p53, p1141 3p53, p1141 ΔBgl, p1141 ΔSpe, p1141 ΔMph, p1142 TAG, p1142 IMIII, p1142 ΔBgl, p1142 ΔSpe, and p1142 ΔMph.
6. Use of the p53 binding region according to any of claims 1 to 3 and/or the vector according to claim 4 or 5 to identify apoptosis-influencing substances.
7. Use according to claim 6, wherein the influence comprises an induction or an inhibition of apoptosis.

TOP SECRET

8. Use according to claim 7, wherein the influence takes place on the basis of a diagnosis and/or therapy of diseases.

9. Use according to claim 8, wherein the diseases comprise viral, liver, neurodegenerative, autoimmune and tumoral diseases.

B⁹ can w
10. A process for influencing apoptosis, comprising the activation or inhibition of the p53 binding region of a CD95 receptor DNA according to any of claims 1 to 3.

11. The process according to claim 10, wherein the influence takes place on the basis of a diagnosis and/or therapy of diseases.

12. The process according to claim 11, wherein the diseases comprise viral, liver, neurodegenerative, autoimmune and tumoral diseases. *B*

add B10

TOEFTHO T62HES60